Bristol-Myers Squibb Company
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-52.9% vs price
Base Case (Median)
-21.3% vs price
Bull Case (75th pct.)
20.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-237.53 | -479.7% | High (40%) |
| PE Comparable | $79.26 | 26.7% | Medium (25%) |
| Growth Trajectory DCF | $49.23 | -21.3% | Medium (20%) |
| Graham Number | $26.93 | -57.0% | Medium (40%) |
| EV/EBITDA | $71.26 | 13.9% | Medium (20%) |
| EV/FCF | $116.69 | 86.5% | Medium (20%) |
| Earnings Power Value | $32.06 | -48.7% | Medium (50%) |
Based on 7 out of 8 methods, BMY appears fairly valued at the current price of $62.56. The base case fair value of $49.23 implies 21.3% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.